Coriell Institute for Medical Research
Catalog ID: NDPT105

Panel Composition and Demographics
Brief Description: This panel contains 5 micrograms of DNA from 92 unique and unrelated White individuals with young onset Parkinson’s disease (YOPD). These include 54 males and 38 females from North America. The age of PD onset ranges from 47 years to 52 years. For all YOPD panels, samples were selected based on age of onset (<56 years). This was defined as when symptom(s) of PD were first noted (including at least one of the following: resting tremor, rigidity, bradykinesis, gait disorder, postural instability). NDPT105 replaces NPDT016, and contains the same samples except: ND04510 (no longer available) and ND02213 (no longer available) are removed and are replaced by ND14538 and ND11132. ND00365 and ND03369 each appear twice on the panel as internal controls. Wells G12 and H12 are empty for addition of a laboratory control.

Panel Design
The concentration of each DNA sample to be plated is normalized and then this concentration is verified. The specific position on the plates has been randomized to reduce any possibility of systematic errors. Four wells remain empty for control samples.

Diagnostic and Clinical Features
The phenotypic details of any single subject can be viewed through the list of panel members by clicking on the individual ID number.

In order for subject inclusion, complete NINDS Repository Clinical Data Elements (CDEs) were required. Furthermore, only subjects who met the UK Brain Bank Criteria idiopathic Parkinson's disease were included (Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. JNNP 1992;55:181-184.). By those criteria, all subjects had bradykinesia, and at least one of the following: muscular rigidity, 4-6 Hz rest tremor, or postural instability (not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction). None had exclusionary features. All had documentation of sustained, excellent response to dopamine replacement therapy.

All samples and data were collected with informed consent under local IRB approved protocols. These samples are generously shared by Drs. Okun Mandel, John Hardy, David Simon, Andrew Singleton, Dennis Dickson, Zbigniew Wszolek, Matthew Farrer, Ray Watts, Burton Scott, Kapil Sethi, Frederick Wooten, Robert Brown, Roger Elble, Melissa Hanson, Ted Dawson, Katrina Gwinn, and John Allman.

Please cite the panel number and the NINDS Repository in any publications, and kindly share those references with the NINDS Repository Management Team at Coriell ( Portions or all of this statement may be used in publications relevant to this panel.

Other Samples, Positive Controls
Samples which may be useful as controls for this panel are additionally available via the NINDS Repository catalogue. Note that positive controls for synuclein triplication and parkin mutation, as well as individuals without Parkinson's or other neurological disease are also available.

Our mission is to prevent and cure disease through biomedical research.


CUSTOMER SERVICE (800) 752-3805 (856) 757-4848

Coriell Institute for Medical Research
403 Haddon Avenue Camden, NJ 08103, USA (856) 966-7377

Ⓒ 2024 Coriell Institute. All rights reserved.